Total reported value
$248.9M
Reporting period: 2026-03-31 · Number of holdings: 38
Rosalind Advisors, Inc. disclosed 38 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $248.9M and a quarterly turnover rate of 69.1%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "R"
Trim VRDN
-44.4% -$9.1M
Trim HELP
-7.6% -$6.2M
Add XERS
+53.0% $2.2M
Add XFOR
+23.4% $2.9M
Trim CGON
-66.7% -$5.7M
Add 76029N906
+452.4% $2.7M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DCTH | Delcath Systems INC | Stock-Other | 12.31% | +0.71% | — | |
| 2 | XERS | Xeris Biopharma Holdings INC | Stock-Other | 7.53% | +1.70% | +53.04% | |
| 3 | FENC | Fennec Pharmaceuticals INC | Stock-Other | 7.19% | +0.12% | +11.28% | |
| 4 | SVRA | Savara INC | Stock-Other | 7.03% | -0.18% | -5.88% | |
| 5 | PCVX | Vaxcyte INC | Stock-Other | 6.77% | +6.77% | NEW | |
| 6 | EYPT | Eyepoint INC | Stock-Other | 5.37% | +0.94% | +50.25% | |
| 7 | XFOR | X4 Pharmaceuticals INC | Stock-Other | 5.33% | +1.67% | +23.36% | |
| 8 | VOR | Vor Biopharma INC | Stock-Other | 5.02% | +5.02% | NEW | |
| 9 | ✓ | Mediwound LTD | Stock-Other | 4.85% | -0.01% | — | |
| 10 | VSTM | Verastem INC | Stock-Other | 4.55% | -0.30% | +19.57% | |
| 11 | CLDX | Celldex Therapeutics INC | Stock-Other | 4.21% | +4.21% | NEW | |
| 12 | BCRX | Biocryst Pharmaceuticals INC | Stock-Other | 3.53% | +3.53% | NEW | |
| 13 | HELP | Cybin INC | Stock-Other | 2.95% | -1.82% | -7.59% | |
| 14 | CGON | Cg Oncology INC | Stock-Other | 2.72% | -1.66% | -66.67% | |
| 15 | NSPR | Inspiremd INC | Stock-Other | 2.56% | +0.12% | — | |
| 16 | AVIR | Atea Pharmaceuticals INC | Stock-Other | 2.53% | +2.53% | NEW | |
| 17 | PROF | Profound Medical CORP | Stock-Other | 2.16% | -0.80% | -22.53% | |
| 18 | VRDN | Viridian Therapeutics INC | Stock-Other | 1.97% | -2.95% | -44.36% | |
| 19 | ✓ | Replimune Group INC | Stock-Other | 1.10% | +1.10% | +452.45% | |
| 20 | ✓ | Polypid LTD | Stock-Other | 1.05% | -0.01% | -14.16% | |
| 21 | MYO | Myomo INC | Stock-Other | 1.04% | -0.19% | +0.20% | |
| 22 | TLPH | Talphera INC | Stock-Other | 1.01% | -0.42% | -6.30% | |
| 23 | OVID | Ovid Therapeutics INC | Stock-Other | 0.99% | +0.99% | NEW | |
| 24 | DFTX | Definium Therapeutics INC | Stock-Other | 0.95% | +0.95% | NEW | |
| 25 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.74% | — | -39.25% | |
| 26 | LPCN | Lipocine INC | Stock-Other | 0.71% | +0.71% | NEW | |
| 27 | NRXS | Neuraxis INC | Stock-Other | 0.68% | +0.31% | — | |
| 28 | AVTX | Avalo Therapeutics INC | Stock-Other | 0.45% | +0.45% | NEW | |
| 29 | ANNX | Annexon INC | Stock-Other | 0.45% | +0.45% | NEW | |
| 30 | ✓ | Stock-Other | 0.42% | -0.64% | -44.44% | ||
| 31 | AQST | Aquestive Therapeutics INC | Stock-Other | 0.42% | +0.42% | NEW | |
| 32 | ✓ | Spdr S&p 500 ETF Tr | ETF-Large Cap & Growth | 0.39% | -0.27% | -75.49% | |
| 33 | BFRI | Biofrontera INC | Stock-Other | 0.38% | +0.15% | +2.03% | |
| 34 | KURA | Kura Oncology INC | Stock-Other | 0.33% | -0.04% | — | |
| 35 | ✓ | Regentis Biomaterials LTD | Stock-Other | 0.31% | -0.29% | — | |
| 36 | ✓ | Viridian Therapeutics INC | Stock-Other | 0.02% | +0.02% | NEW | |
| 37 | ✓ | Arrivent Biopharma INC | Stock-Other | — | -0.19% | +0.93% | |
| 38 | ✓ | Uniqure NV | Stock-Other | — | -0.03% | +195.80% |
Performance for Q3 2026
+30.2%
Performance Last 4 Quarters
+36.2%
Based on 67% of reported portfolio value with available pricing
Not enough sector-mapped data yet
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 38 | $248.9M | 69 | |
| 2025-12-31 | 42 | $284.5M | 49 | |
| 2025-09-30 | 39 | $292.6M | 87 | |
| 2025-06-30 | 37 | $210.9M | 0 | |
| 2025-03-31 | 34 | $205.6M | 0 | |
| 2024-12-31 | 40 | $195.6M | 0 | |
| 2024-09-30 | 33 | $156.2M | 0 | |
| 2024-06-30 | 40 | $130.0M | 0 | |
| 2024-03-31 | 34 | $107.0M | 0 | |
| 2023-12-31 | 30 | $121.4M | 0 |
Rosalind Advisors, Inc.'s most significant position changes for 2026-03-31: New buy: Vaxcyte INC (PCVX); Sold out: Replimune Group INC (REPL); Sold out: Atyr Pharma INC (ATYR); New buy: Vor Biopharma INC (VOR); Sold out: Cytokinetics INC (CYTK).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XERS | Xeris Biopharma Holdings INC | +1.7% | +53.04% | Add |
| 2 | XFOR | X4 Pharmaceuticals INC | +1.7% | +23.36% | Add |
| 3 | ✓ | Replimune Group INC | +1.1% | +452.45% | Add |
| 4 | EYPT | Eyepoint INC | +0.9% | +50.25% | Add |
| 5 | DCTH | Delcath Systems INC | +0.7% | — | Unchanged |
| 6 | NRXS | Neuraxis INC | +0.3% | — | Unchanged |
| 7 | BFRI | Biofrontera INC | +0.2% | +2.03% | Add |
| 8 | FENC | Fennec Pharmaceuticals INC | +0.1% | +11.28% | Add |
| 9 | NSPR | Inspiremd INC | +0.1% | — | Unchanged |
| 10 | OKUR | Onkure Therapeutics Inc-a | — | -39.25% | Trim |
| 11 | ✓ | Mediwound LTD | 0% | — | Unchanged |
| 12 | ✓ | Polypid LTD | 0% | -14.16% | Trim |
| 13 | ✓ | Uniqure NV | 0% | +195.80% | Add |
| 14 | KURA | Kura Oncology INC | 0% | — | Unchanged |
| 15 | SVRA | Savara INC | -0.2% | -5.88% | Trim |
| 16 | MYO | Myomo INC | -0.2% | +0.20% | Add |
| 17 | ✓ | Arrivent Biopharma INC | -0.2% | +0.93% | Add |
| 18 | ✓ | Spdr S&p 500 ETF Tr | -0.3% | -75.49% | Trim |
| 19 | ✓ | Regentis Biomaterials LTD | -0.3% | — | Unchanged |
| 20 | VSTM | Verastem INC | -0.3% | +19.57% | Add |
| 21 | TLPH | Talphera INC | -0.4% | -6.30% | Trim |
| 22 | ✓ | -0.6% | -44.44% | Trim | |
| 23 | PROF | Profound Medical CORP | -0.8% | -22.53% | Trim |
| 24 | CGON | Cg Oncology INC | -1.7% | -66.67% | Trim |
| 25 | HELP | Cybin INC | -1.8% | -7.59% | Trim |
| 26 | VRDN | Viridian Therapeutics INC | -3% | -44.36% | Trim |
| 27 | PCVX | Vaxcyte INC | — | NEW | New buy |
| 28 | REPL | Replimune Group INC | — | EXIT | Sold out |
| 29 | ATYR | Atyr Pharma INC | — | EXIT | Sold out |
| 30 | VOR | Vor Biopharma INC | — | NEW | New buy |
| 31 | CYTK | Cytokinetics INC | — | EXIT | Sold out |
| 32 | CLDX | Celldex Therapeutics INC | — | NEW | New buy |
| 33 | BRD1EUR | Mind Medicine Mindmed INC | — | EXIT | Sold out |
| 34 | BCRX | Biocryst Pharmaceuticals INC | — | NEW | New buy |
| 35 | AVIR | Atea Pharmaceuticals INC | — | NEW | New buy |
| 36 | OCUL | Ocular Therapeutix INC | — | EXIT | Sold out |
| 37 | AVBP | Arrivent Biopharma INC | — | EXIT | Sold out |
| 38 | OVID | Ovid Therapeutics INC | — | NEW | New buy |
| 39 | DFTX | Definium Therapeutics INC | — | NEW | New buy |
| 40 | ✓ | Anavex Life Sciences CORP | — | EXIT | Sold out |
| 41 | LPCN | Lipocine INC | — | NEW | New buy |
| 42 | ✓ | Spdr Series Trust | — | EXIT | Sold out |
| 43 | TRVI | Trevi Therapeutics INC | — | EXIT | Sold out |
| 44 | AVTX | Avalo Therapeutics INC | — | NEW | New buy |
| 45 | ✓ | Ishares Tr | — | EXIT | Sold out |
| 46 | ANNX | Annexon INC | — | NEW | New buy |
| 47 | AQST | Aquestive Therapeutics INC | — | NEW | New buy |
| 48 | GUTS | Fractyl Health INC | — | EXIT | Sold out |
| 49 | ✓ | Verastem INC | — | EXIT | Sold out |
| 50 | ✓ | Viridian Therapeutics INC | — | NEW | New buy |
Institutions with a similar AUM
CIK 0001904152
Total reported value
$248.9M
92 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001929349
Total reported value
$248.8M
89 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001666667
Total reported value
$248.8M
81 stks
2022-12-31
Stale — no recent filing
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001346824
Total reported value
$9.4B
86 stks
2026-03-31
1 of the top 5 holdings overlap, including Vaxcyte INC
CIK 0001397144
Total reported value
$306.9M
19 stks
2022-12-31
Stale — no recent filing
1 of the top 5 holdings overlap, including Vaxcyte INC
CIK 0001512848
Total reported value
$1.8B
26 stks
2026-03-31
1 of the top 5 holdings overlap, including Savara INC